Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Longeveron (NASDAQ: LGVN) reported a narrower third-quarter net loss while reviewing strategic alternatives after its ELPIS II trial missed its primary endpoint. Net loss was $6.135 million, or $1.91 per share, versus $7.221 million, or $3.93 per share, a year earlier. Revenue fell to $115,000 from $137,000.
The 40-infant trial missed its primary measure of heart pumping function at Month 12. A secondary analysis found 8 major adverse cardiac events with standard care versus 1 with laromestrocel (P=0.043). Longeveron requested an FDA meeting to determine potential next steps. It retained Lucid Capital Markets to explore alternatives, including a potential business combination, and implemented cash conservation measures. Cash was $7.245 million at September 30; the company expects funding into the first quarter of 2027. A 1-for-10 reverse split of Class A and Class B common stock took effect August 26, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter net loss narrowed to $6.135 million from $7.221 million; loss per share improved to $1.91 from $3.93.
- Moderate pointStrategic review includes partnership, investment, financing, sale, merger or business combination; Lucid Capital Markets retained.
- Moderate pointThird-quarter other income increased to $1.062 million from $89,000, primarily including a $1.0 million XPRIZE award. 11% of market cap
- Moderate pointCash and cash equivalents rose to $7.245 million at September 30, 2026, from $4.661 million at December 31, 2025.
- Minor pointELPIS II secondary cardiac-event analysis showed 1 event with laromestrocel versus 8 with standard care (P=0.043).
11 minor points
- Minor pointELPIS II pre-specified secondary endpoints associated laromestrocel with fewer adjudicated clinical and safety events than standard care.
- Minor pointCash conservation measures have been implemented to contain costs.
- Minor pointThird-quarter general and administrative expenses decreased to $3.310 million from $3.583 million a year earlier.
- Minor pointThird-quarter clinical trial revenue increased to $115,000 from $94,000 a year earlier.
- Minor pointNine-month net loss narrowed to $16.944 million from $17.260 million; loss per share improved to $5.75 from $10.70.
- Minor pointNine-month clinical trial revenue increased to $780,000 from $651,000 a year earlier.
- Minor pointNine-month cost of revenues decreased to $283,000 from $288,000 a year earlier.
- Minor pointNine-month other income increased to $1.199 million from $628,000 a year earlier.
- Minor pointPediatric cardiomyopathy IND became effective in July 2025, permitting a single Phase 2 registrational trial.
- Minor point. Forward-looking: it has not happened yet and may not happen.Alzheimer’s program advancement is the subject of company efforts to secure collaborations or partnerships.
- Minor point. Forward-looking: it has not happened yet and may not happen.XPRIZE finalist status offers competition for up to $81 million, subject to trial completion and financing.
Negative
- Major pointELPIS II missed its primary efficacy endpoint: change in right ventricular ejection fraction at Month 12.
- Major pointClass A shares outstanding increased to 3,113,450 from 2,144,534 at December 31, 2025, diluting existing holders.
- Moderate pointHLHS development next steps remain undetermined; an FDA meeting has been requested to review results.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Cash runway extends only into the first quarter of 2027, based on company forecasts and ongoing conservation measures.
- Moderate pointStrategic alternatives remain under evaluation, with no definitive completion timeline.
- Moderate pointTotal liabilities increased to $7.305 million at September 30, 2026, from $4.586 million at December 31, 2025.
13 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.XPRIZE Grand Prize eligibility depends on successful completion and financing of the required clinical trial.
- Minor pointThird-quarter revenue declined to $115,000 from $137,000 a year earlier.
- Minor pointThird-quarter contract manufacturing and related lease revenue fell to $0 from $37,000 and $6,000, respectively.
- Minor pointThird-quarter gross profit declined to $71,000 from $125,000 a year earlier.
- Minor pointThird-quarter cost of revenues increased to $44,000 from $12,000 a year earlier.
- Minor pointThird-quarter research and development expenses rose to $3.958 million from $3.852 million a year earlier.
- Minor pointNine-month revenue declined to $800,000 from $834,000 a year earlier.
- Minor pointNine-month contract manufacturing revenue fell to $20,000 from $165,000; related lease revenue fell to $0 from $18,000.
- Minor pointNine-month gross profit declined to $517,000 from $546,000 a year earlier.
- Minor pointNine-month general and administrative expenses increased to $9.189 million from $9.113 million a year earlier.
- Minor pointNine-month research and development expenses increased to $9.471 million from $9.321 million a year earlier.
- Minor pointNine-month operating loss widened to $18.143 million from $17.888 million a year earlier.
- Minor pointStockholders’ equity declined to $4.710 million at September 30, 2026, from $5.675 million at December 31, 2025.
News Explained
No strategic transaction is committed; the September balance sheet shows more Class A shares and convertible preferred shares, with conversion effects unspecified.
Longeveron is evaluating strategic and financing options, including investment, additional financing, sale, merger or a business combination, with no definitive timeline and no assurance of a transaction; no related funding or ownership change is committed in this release.
As of
The higher Class A count means an unchanged Class A holding represents a smaller fraction of that class; the release gives no conversion terms for the preferred shares, so their effect on common ownership cannot be assessed.
Key Figures
- ELPIS II enrollment
- 40 infants
- Phase 2b trial in HLHS
- MACE events
- 8 vs. 1; P=0.043
- Pre-specified secondary endpoint; standard-of-care vs. laromestrocel
- Revenue decrease
- $22,000 (16%)
- Q3 2026 compared with Q3 2025
- Net loss
- $6.1 million vs. $7.2 million
- Three months ended September 30, 2026 vs. 2025
- Cash and cash equivalents
- $7.2 million
- As of September 30, 2026
- Anticipated cash runway
- Into the first quarter of 2027
- Based on current operating budget, cash flow forecast, and cash conservation measures
Previous Earnings Reports
-
Reported $10.1 million cash and runway into Q4 2026 as net loss widened.
-
Closed a private placement, with $15 million initially funded, and reported runway into Q4 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
rvef medical
mace medical
rmat regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Following reporting of results for the ELPIS II Phase 2b clinical trial, the Company has requested a meeting with the FDA to review the results to determine potential next steps for the HLHS development program
- The Company has initiated a process to review all strategic options with a goal of maximizing stockholder value and has implemented cash conservation measures to optimize cost containment
- Lucid Capital Markets retained as the Company’s financial advisor to explore potential strategic opportunities, including a potential business combination
MIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended September 30, 2026 and provided a business update.
“With ELPIS II results now available, we have requested a meeting with the FDA to determine potential next steps for the HLHS development program,” said Stephen H. Willard, Chief Executive Officer of Longeveron. “At the same time, we continue to review potential strategic alternatives for the Company as we explore all opportunities to maximize value for our stockholders.”
Evaluation of Strategic and Financing Alternatives
The Company is evaluating a range of strategic and financing alternatives with a goal of maximizing stockholder value. These alternatives may include, among others, a strategic partnership or investment, additional financing, a sale or merger of the Company, or a business combination. The Company has retained Lucid Capital Markets, LLC as the Company’s financial advisor for this process.
The Company has not set a definitive timeline for completion of this process and does not intend to disclose further developments unless and until it is determined that further disclosure is appropriate or required by law. There can be no assurance that this process will result in any transaction or other strategic outcome, or that such transaction or outcome will be completed on favorable terms.
Development Programs
Longeveron’s investigational therapeutic candidate laromestrocel (Lomecel-B®) is a proprietary, scalable, allogeneic cellular therapy.
Hypoplastic Left Heart Syndrome (HLHS) – a rare pediatric congenital heart birth defect in which the left ventricle (one of the pumping chambers of the heart) is either severely underdeveloped or missing.
- In September and October, the Company announced topline and updated, respectively, results from ELPIS II, its Phase 2b clinical trial evaluating its laromestrocel as an adjunct to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome (HLHS). The ELPIS II trial did not meet the primary efficacy endpoint of change from baseline in right ventricular ejection fraction (RVEF) at Month 12. Based on the pre-specified secondary endpoints, laromestrocel was associated with fewer adjudicated clinical and safety events than the standard of care (SOC) arm. Additional review of the pre-specified secondary endpoint major adverse cardiac events (MACE) showed statistical significance with 8 events in the SOC arm versus 1 in the laromestrocel treatment arm (P=0.043).
- The Company has requested a meeting with the U.S. Food and Drug Administration (FDA) to review the results to determine potential next steps for the HLHS development program.
- The FDA has granted laromestrocel Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation for the treatment of HLHS.
Pediatric Dilated Cardiomyopathy (PDCM) – a rare pediatric cardiovascular disease in which the muscles in one or more of the heart chambers become enlarged or stretched (dilated), with nearly
- Longeveron’s Investigational New Drug (IND) application for its stem cell therapy laromestrocel as a potential treatment for PDCM became effective in July 2025. This IND provides for moving directly to a single Phase 2 registrational clinical trial.
Alzheimer’s disease (AD) – a neurodegenerative disorder that leads to progressive memory loss and death and currently has very limited therapeutic options.
- The Company is seeking to forge strategic collaborations and/or partnerships for the advancement of laromestrocel in addressing AD.
- The FDA has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease.
Aging-related Frailty (AF) – a chronic condition driven by systemic physiologic decline, characterized by reduced reserve and resilience across multiple organ systems with common features including weakness, fatigue, weight loss, slowness and reduced activity. No FDA-approved therapies currently exist.
- Laromestrocel data from its Phase 2b clinical trial in Aging-related Frailty were published in Cell Stem Cell in February 2026.
- In August, the Company announced that it has been selected as a Finalist Team in the XPRIZE Healthspan global competition, a seven-year,
$101 million global competition to identify therapeutic approaches to increase human healthspan. As a result, the Company was one of 10 finalist teams to receive a$1.0 million Milestone 2 Award to be used in accordance with the XPRIZE competition rules with the opportunity to compete for the XPRIZE Grand Prize of up to$81 million , subject to the successful completion of the required clinical trial and financing thereof.
Corporate Updates
- In July, the Company announced that Deborah Ascheim, M.D., was elected to the Longeveron Board of Directors. Dr. Ascheim is a strategic biotech Chief Medical Officer and physician who has over 30 years of clinical and executive experience advancing breakthrough therapies, including gene, cell, and biologics, for rare, ultra-rare, and common diseases across multiple indications.
- In August, the Company appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Chief Financial Officer (CFO), principal financial officer and principal accounting officer. Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector.
- Effective August 26, 2026, at 11:59 p.m. Eastern Time, the Company implemented a 1-for-10 reverse split of the shares of its Class A common stock, par value
$0.001 per share and Class B common stock, par value$0.001 per share (collectively, the “Common Stock”), whether issued and outstanding or held by the Company as treasury stock. - In September, the Company announced it had initiated a process to review all strategic options with the goal of maximizing stockholder value. In conjunction with this process, the Company has implemented cash conservation measures to optimize cost containment.
- In October, the Company announced the retention of Lucid Capital Markets as the Company’s financial advisor to explore potential strategic opportunities.
2026 Third Quarter Summary Financial Results
- Revenues, Cost of Revenues and Gross Profit: Revenues for each of the three-month periods ended September 30, 2026 and September 30, 2025 was
$0.1 million . 2026 revenues decreased by$22,000 , or16% , when compared to the same period in 2025, primarily due to the absence of contract manufacturing revenue.
Clinical trial revenue, which is derived from The Bahamas Registry Trial, for each of the three-month periods ended September 30, 2026 and September 30, 2025 was
Related cost of revenues were
-
- General and Administrative Expenses: General and administrative expenses for the three months ended September 30, 2026 were
$3.3 million , compared to$3.6 million for the same period in 2025. The decrease of$0.3 million , or8% , was primarily due to a$0.9 million decrease in personnel-related costs, partially offset by an increase in legal fees of$0.3 million and finance costs of$0.3 million . - Research and Development Expenses: Research and development expenses for the three months ended September 30, 2026 were
$4.0 million , compared to$3.9 million for the same period in 2025. The increase of$0.1 million , or3% , was due to higher ELPIS II clinical trial expenses of$0.7 million , partially offset by supplies and costs associated with technology transfer of$0.6 million recorded in 2025. - Other Income: Other income for the three months ended September 30, 2026 was
$1.1 million , primarily consisting of$1.0 million received as a recipient of a Milestone 2 Award in the XPRIZE Healthspan competition and$0.1 million of interest earned on money market funds. Other income for the three months ended September 30, 2025, was$0.1 million , primarily consisting of interest earned on money market funds. - Net Loss: Net loss was
$6.1 million for the three months ended September 30, 2026, compared to$7.2 million for the three months ended September 30, 2025. The decrease of$1.1 million , or15% , was due to the factors outlined above. - Cash and cash equivalents: As of September 30, 2026, the Company had cash and cash equivalents of
$7.2 million . The Company currently anticipates its existing cash and cash equivalents will enable it to fund its operating expenses and capital expenditure requirements into the first quarter of 2027, based on its current operating budget, cash flow forecast, as well as the ongoing implementation of cash conservation measures to optimize cost containment.
- General and Administrative Expenses: General and administrative expenses for the three months ended September 30, 2026 were
Conference Call
In light of the Company's ongoing review of strategic alternatives, the Company has determined not to hold a conference call to review its third quarter results at this time.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product candidate is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. We believe laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including the occurrence and outcome of a meeting or discussion of ELPIS II results with the FDA and the future of the HLHS development program; our ability to pursue funding sources and potential revenue opportunities to advance laromestrocel in longevity and Aging-related frailty; our expectations regarding the review and exploration of all strategic options and their potential impact on stockholder value; the possibility of a strategic partnership or investment, additional financing, sale or merger of the Company, or a business combination; the timeline and disclosure of events involving our strategic review process the impact of our retention of a financial advisor and our ability to engage additional strategic advisors or an investment bank; the continued listing of our Class A common stock on Nasdaq; our expectations regarding the future of the company's operations, including our clinical, development and commercialization activities; our implementation of cash conservation measures to reduce operating expenses and optimize cost containment; the impact of the results of the ELPIS II trial upon future revenues; and other statements regarding future events. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, although not all forward-looking statements contain these words, or by discussion of strategy or goals or other future events, circumstances, or effects. Additional factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the risk that the exploration of strategic options may not result in any definitive transaction or enhance stockholder value or may create uncertainty that may adversely affect our business, financial condition, results of operations, or stockholder and investor perception; our ability to successfully contain costs, attain future financing, funding sources, or secure strategic partnerships or other alternatives on terms favorable to us or at all; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; our ability to successfully transition toward a more capital-efficient, asset-light operating model; our ability to secure one or more strategic licensing partnerships for laromestrocel in our development programs; our ability to reach alignment with the FDA and other regulatory authorities on a potential path toward regulatory approval; the availability of evidence from our ongoing and future preclinical studies and clinical trials sufficient to support the Company filing a BLA for the investigational product candidate for one or more indications; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the size of the market opportunity for certain of our investigational product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the investigational product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our investigational product candidates; our ability to obtain and maintain regulatory approval of our investigational product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our investigational product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the our ability to attract and retain personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 17, 2026, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in a highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor and Media Inquiries:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
---tables follow---
| Longeveron Inc. Condensed Balance Sheets (In thousands, except share and per share data) | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 7,245 | $ | 4,661 | ||||
| Prepaid expenses and other current assets | 840 | 686 | ||||||
| Accounts receivable | 64 | 104 | ||||||
| Total current assets | 8,149 | 5,451 | ||||||
| Property and equipment, net | 1,445 | 1,836 | ||||||
| Intangible assets, net | 2,167 | 2,285 | ||||||
| Operating lease asset, net | 246 | 513 | ||||||
| Other assets | 8 | 176 | ||||||
| Total assets | $ | 12,015 | $ | 10,261 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,961 | $ | 423 | ||||
| Accrued expenses | 3,714 | 2,969 | ||||||
| Current portion of lease liability | 412 | 655 | ||||||
| Deferred revenue | 40 | 40 | ||||||
| Other current liabilities | 400 | — | ||||||
| Total current liabilities | 6,527 | 4,087 | ||||||
| Long-term liabilities: | ||||||||
| Long-term portion of operating lease liability | — | 169 | ||||||
| Liability related to the sale of future PRV proceeds | 778 | — | ||||||
| Other liabilities | — | 330 | ||||||
| Total long-term liabilities | 778 | 499 | ||||||
| Total liabilities | 7,305 | 4,586 | ||||||
| Commitments and contingencies (Note 9) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, | — | — | ||||||
| Series A non-voting convertible preferred stock, | — | — | ||||||
| Class A common stock, | 3 | 2 | ||||||
| Class B common stock, 138,405 shares issued and outstanding at September 30, 2026; 148,401 shares issued and outstanding at December 31, 2025 | — | — | ||||||
| Additional paid-in capital | 153,962 | 137,984 | ||||||
| Accumulated deficit | (149,255 | ) | (132,311 | ) | ||||
| Total stockholders’ equity | 4,710 | 5,675 | ||||||
| Total liabilities and stockholders’ equity | $ | 12,015 | $ | 10,261 | ||||
See accompanying notes to financial statements.
| Longeveron Inc. Condensed Statements of Operations (In thousands, except per share data) (Unaudited) | ||||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues | ||||||||||||||||
| Clinical trial revenue | $ | 115 | $ | 94 | $ | 780 | $ | 651 | ||||||||
| Contract manufacturing lease revenue | — | 6 | — | 18 | ||||||||||||
| Contract manufacturing revenue | — | 37 | 20 | 165 | ||||||||||||
| Total revenues | 115 | 137 | 800 | 834 | ||||||||||||
| Cost of revenues | 44 | 12 | 283 | 288 | ||||||||||||
| Gross profit | 71 | 125 | 517 | 546 | ||||||||||||
| Operating expenses | ||||||||||||||||
| General and administrative | 3,310 | 3,583 | 9,189 | 9,113 | ||||||||||||
| Research and development | 3,958 | 3,852 | 9,471 | 9,321 | ||||||||||||
| Total operating expenses | 7,268 | 7,435 | 18,660 | 18,434 | ||||||||||||
| Loss from operations | (7,197 | ) | (7,310 | ) | (18,143 | ) | (17,888 | ) | ||||||||
| Other income | ||||||||||||||||
| Other income, net | 1,062 | 89 | 1,199 | 628 | ||||||||||||
| Total other income, net | 1,062 | 89 | 1,199 | 628 | ||||||||||||
| Net loss | $ | (6,135 | ) | $ | (7,221 | ) | $ | (16,944 | ) | $ | (17,260 | ) | ||||
| Basic and diluted net loss per share | $ | (1.91 | ) | $ | (3.93 | ) | $ | (5.75 | ) | $ | (10.70 | ) | ||||
| Basic and diluted weighted average common shares outstanding | 3,211,122 | 1,837,321 | 2,945,188 | 1,612,488 | ||||||||||||
See accompanying notes to financial statements.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cde71c09-a5f1-424d-837b-80f8786d82a5
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Longeveron’s third-quarter 2026 earnings results?
Longeveron reported a $6.135 million net loss, or $1.91 per share, for the quarter ended September 30, 2026. The year-earlier loss was $7.221 million, or $3.93 per share. Quarterly revenue declined to $115,000 from $137,000.
What did Longeveron’s ELPIS II trial show?
The 40-infant Phase 2b trial did not meet its primary endpoint of change from baseline in right ventricular ejection fraction, a measure of heart pumping function, at Month 12. Additional review of the pre-specified major adverse cardiac events endpoint found 8 events with standard care versus 1 with laromestrocel (P=0.043).
What FDA designations does Longeveron’s laromestrocel have?
Laromestrocel has Orphan Drug, Fast Track and Rare Pediatric Disease designations for hypoplastic left heart syndrome. For mild Alzheimer’s disease, it has Regenerative Medicine Advanced Therapy and Fast Track designations.
Will Longeveron hold a conference call for its third-quarter 2026 results?
Longeveron will not hold a third-quarter results conference call at this time. The company gives its ongoing review of strategic alternatives as the reason.